Taiwan Advance Bio-Pharmaceutical (ROCO:4186) EBIT: NT$33.7 Mil (TTM As of Dec. 2025)

Taiwan Advance Bio-Pharmaceutical  (ROCO:4186) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Taiwan Advance Bio-Pharmaceutical's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Taiwan Advance Bio-Pharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

where Working Capital is:

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Taiwan Advance Bio-Pharmaceutical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Advance Bio-Pharmaceutical EBIT Related Terms

The historical data trend for Taiwan Advance Bio-Pharmaceutical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Advance Bio-Pharmaceutical EBIT Chart

Taiwan Advance Bio-Pharmaceutical Annual Data
	Trend	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24	Dec25
EBIT		Get a 7-Day Free Trial					-107.01	9.82	-4.09	30.03	33.68

Taiwan Advance Bio-Pharmaceutical Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
EBIT	Get a 7-Day Free Trial															28.91	-0.63	30.66	-0.73	34.41

ROCO:4186 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Taiwan Advance Bio-Pharmaceutical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taiwan Advance Bio-Pharmaceutical EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taiwan Advance Bio-Pharmaceutical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Taiwan Advance Bio-Pharmaceutical's EV-to-EBIT falls into.

Taiwan Advance Bio-Pharmaceutical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$33.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Advance Bio-Pharmaceutical Business Description